The Rubivirus Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Rubivirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rubivirus Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rubivirus Infections and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Rubivirus Infections by 12 companies/universities/institutes. The top development phase for Rubivirus Infections is phase iii with five drugs in that stage. The Rubivirus Infections pipeline has 11 drugs in development by companies and two by universities/ institutes. Some of the companies in the Rubivirus Infections pipeline products market are: Beijing Minhai Biotechnology, Vaxxas and Daiichi Sankyo.
The key mechanisms of action in the Rubivirus Infections pipeline product include The Rubivirus Infections pipeline products include two routes of administration with the top ROA being Subcutaneous and two key molecule types in the Rubivirus Infections pipeline products market including Live Attenuated Vaccine, and Vaccine.
Rubivirus Infections overview
Rubi virus Infections causes rubella and is placed in the Rubi virus genus of togaviridae family. It is a single stranded RNA virus causing infections most predominantly in children and is also known as German measles. Mode of transmission is through droplets contacts and spreads to other organs. It can also transmit from mother to fetus through placenta. In most cases it is asymptomatic but commonly characterized by a rash, lymphadenopathy, joint pains, prematurity, CNS symptoms and rarely jaundice, hemolytic anemia, pneumonitis are seen. CBP to find out the levels of platelets, virus culture and other serology studies are conducted. Infection can be prevented by rubella vaccine commonly MMR vaccine for children and also recommended during pregnancy.
For a complete picture of Rubivirus Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
